AFP and cancer: When the evaluation of diagnostic power was conducted using each cutoff value, levels of CA19-9, SPan-1, and CEA as well as the fAGP in patients with malignant tumors indicated differences from those in benign diseases but no such differences were present with the levels of DUPAN-2, AFP, or PIVKA-II.